Total Payments
$4,430
2022 Payments
$49.68
Companies
42
Transactions
269
Medicare Patients
314
Medicare Billing
$42,423
Payment Breakdown by Category
Food & Beverage$4,423 (99.9%)
Education$6.25 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,423 | 268 | 99.9% |
| Education | $6.25 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $569.23 | 31 | $0 (2018) |
| Genentech USA, Inc. | $493.26 | 40 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $427.86 | 28 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $410.74 | 25 | $0 (2020) |
| Celgene Corporation | $368.14 | 15 | $0 (2018) |
| Amgen Inc. | $236.15 | 13 | $0 (2018) |
| Janssen Biotech, Inc. | $174.38 | 9 | $0 (2018) |
| Lilly USA, LLC | $155.43 | 11 | $0 (2018) |
| PFIZER INC. | $154.01 | 12 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $141.72 | 10 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $49.68 | 2 | Regeneron Healthcare Solutions, Inc. ($33.80) |
| 2020 | $154.66 | 3 | Novocure Inc. ($129.10) |
| 2019 | $78.24 | 6 | Genentech USA, Inc. ($35.43) |
| 2018 | $1,214 | 78 | Novartis Pharmaceuticals Corporation ($146.42) |
| 2017 | $2,933 | 180 | E.R. Squibb & Sons, L.L.C. ($461.46) |
All Payment Transactions
269 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/10/2022 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $33.80 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2022 | GENZYME CORPORATION | LIBTAYO (Biological), LIBTAYO, LIBTAYO | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Oncology | ||||||
| 03/06/2020 | Novocure Inc. | Oncology (Device) | Food and Beverage | Cash or cash equivalent | $129.10 | General |
| Category: Optune Lua | ||||||
| 02/10/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: ONCOLOGY | ||||||
| 02/03/2020 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: BioOncology | ||||||
| 12/09/2019 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Oncology | ||||||
| 11/04/2019 | Genentech USA, Inc. | GAZYVA (Biological) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: BioOncology | ||||||
| 10/29/2019 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $12.04 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/21/2019 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: BioOncology | ||||||
| 05/31/2019 | Genentech USA, Inc. | GAZYVA (Biological) | Food and Beverage | In-kind items and services | $11.09 | General |
| Category: BioOncology | ||||||
| 03/25/2019 | Clovis Oncology, Inc. | Rubraca (Drug) | Food and Beverage | In-kind items and services | $12.04 | General |
| Category: Oncology | ||||||
| 12/17/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.56 | General |
| Category: Oncology | ||||||
| 12/11/2018 | Genentech USA, Inc. | GAZYVA (Biological), Rituxan Hycela | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: BioOncology | ||||||
| 11/27/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.81 | General |
| Category: Oncology | ||||||
| 11/19/2018 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $11.05 | General |
| Category: BioOncology | ||||||
| 11/05/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.31 | General |
| Category: Oncology | ||||||
| 10/19/2018 | Taiho Oncology, Inc. | Lonsurf (Drug) | Food and Beverage | In-kind items and services | $10.93 | General |
| Category: Oncology | ||||||
| 08/06/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $6.25 | General |
| Category: Oncology | ||||||
| 07/16/2018 | INSYS Therapeutics Inc | SYNDROS (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Chemotherapy-Induced Nausea and Vomiting | ||||||
| 07/10/2018 | Genentech USA, Inc. | Alecensa (Biological), TECENTRIQ | Food and Beverage | In-kind items and services | $8.56 | General |
| Category: BioOncology | ||||||
| 06/25/2018 | Genentech USA, Inc. | GAZYVA (Biological), Rituxan Hycela | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: BioOncology | ||||||
| 06/20/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: Oncology | ||||||
| 06/18/2018 | PFIZER INC. | XALKORI (Drug), IBRANCE | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.53 | General |
| Category: Oncology | ||||||
| 06/08/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 78 | 138 | $39,973 | $10,422 |
| 2021 | 6 | 110 | 208 | $61,162 | $16,545 |
| 2020 | 6 | 126 | 207 | $58,986 | $15,456 |
Total Patients
314
Total Services
553
Medicare Billing
$42,423
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 56 | $16,528 | $4,465 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 28 | 56 | $15,904 | $4,005 | 25.2% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 26 | 26 | $7,541 | $1,953 | 25.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 91 | $25,480 | $6,715 | 26.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 29 | 60 | $17,280 | $4,826 | 27.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $6,744 | $1,890 | 28.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 14 | 16 | $4,768 | $1,335 | 28.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 15 | 15 | $4,230 | $1,112 | 26.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 14 | $2,660 | $665.93 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 49 | $14,014 | $4,113 | 29.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 51 | $14,994 | $3,087 | 20.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $8,340 | $2,435 | 29.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 20 | 36 | $7,200 | $2,089 | 29.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 16 | 16 | $4,464 | $1,312 | 29.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 21 | $6,174 | $1,309 | 21.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 19 | 19 | $3,800 | $1,111 | 29.2% |
About Dr. Gregory Long, MD
Dr. Gregory Long, MD is a Hematology & Oncology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1952303471.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Long, MD has received a total of $4,430 in payments from pharmaceutical and medical device companies, with $49.68 received in 2022. These payments were reported across 269 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($4,423).
As a Medicare-enrolled provider, Long has provided services to 314 Medicare beneficiaries, totaling 553 services with total Medicare billing of $42,423. Data is available for 3 years (2020–2022), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Pittsburgh, PA
- Active Since 08/15/2005
- Last Updated 10/12/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1952303471
Products in Payments
- OPDIVO (Biological) $417.77
- KEYTRUDA (Biological) $184.32
- Avastin (Biological) $176.00
- JADENU (Drug) $131.06
- Oncology (Device) $129.10
- TECENTRIQ (Biological) $126.38
- Neulasta (Biological) $105.80
- CYRAMZA (Drug) $105.30
- Abraxane (Drug) $95.84
- ZYTIGA (Drug) $89.01
- EMEND (Drug) $86.51
- GAZYVA (Biological) $84.01
- Revlimid (Drug) $82.45
- KISQALI (Drug) $80.48
- GILOTRIF (Drug) $76.49
- MEKINIST (Drug) $71.93
- Venclexta (Drug) $71.62
- IMBRUVICA (Drug) $68.99
- XTANDI (Drug) $65.36
- Xofigo (Drug) $63.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Pittsburgh
Salman Fazal, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Cyrus Khan, M.d, M.D
Hematology & Oncology — Payments: $2.2M
Hematology & Oncology $2.2M
Dr. Alexander Barsouk, Md, MD
Hematology & Oncology — Payments: $905,454
Hematology & Oncology $905,454
Taofeek Owonikoko, M.d, M.D
Hematology & Oncology — Payments: $454,396
Hematology & Oncology $454,396
Dr. Hashem Younes, M.d, M.D
Hematology & Oncology — Payments: $451,665
Hematology & Oncology $451,665
Dr. Jason Luke, M.d, M.D
Hematology & Oncology — Payments: $431,360
Hematology & Oncology $431,360